Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Circulatory System Drugs API  > Fenofibrate CAS 49562-28-9 proctofene sedufen lipidax lipifen

Fenofibrate CAS 49562-28-9 proctofene sedufen lipidax lipifen 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Production Capacity: 100 Ton/Year
Delivery Date: Within 7 days
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
CAS: 49562-28-9

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia.

Fenofibrate(CAS: 49562-28-9)



Molecular formula


Molecular weight





Off-white powder

Melting point


 Storage   Condition

Store at RT


Fenofibrate (Tricor) is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglycerides level. It is used alone or along with statins in the treatment of hypercholesterolemia andhypertriglyceridemia.

Fenofibrate has been used since 1975, is one of the most commonly prescribed fibrates, and has a well known efficacy and tolerability profile.

Medical uses

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesterol, triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia.

Severe hypertriglyceridemia type IV or V

Indicated as an adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.

Three randomized, double-blind trials have shown that treatment with fenofibric acid plus a statin improved HDL and triglyceride levels better than a statin alone and improved LDL levels better than fenofibric acid monotherapy.

Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus.

Additionally, in Europe, fenofibrate is indicated in mixed hyperlipidemia in those with high cardiovascular risk in addition to a statin when triglycerides and HDL are not adequately controlled.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: